Cannabis investments are set to get hyper-focused, says a new report from a big Canadian bank.

In a note issued to investors last Thursday (March 12), John Zamparo, an analyst with CIBC Capital Markets and a tough critic of the cannabis space, indicated that after evaluating balance sheets, cash burn rates and available liquidity he is suggesting very specific cannabis companies.

The analyst said Cronos Group (NASDAQ:CRON,TSX:CRON) and Canopy Rivers (TSX:RIV,OTC Pink:CNPOF) are “the most ideal names to own in the current environment.” He added that Canopy Growth’s (NYSE:CGC,TSX:WEED) status as the leading company in the Canadian industry will maintain investor attention.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“We believe focus among cannabis investors has shifted to minimizing downside; in other words, evaluating cannabis stocks from a liquidation perspective, simply comparing market capitalization to net cash balances,” Zamparo wrote in his note.

On the other side of the market, Zamparo highlighted HEXO (NYSE:HEXO,TSX:HEXO), Sundial Growers (NASDAQ:SNDL) and Aurora Cannabis (NYSE:ACB,TSX:ACB) as companies on the verge of continued pressure “as scrutiny increases on producers who have assumed debt or utilized convertible debentures for financing.”

The analyst is not optimistic about the short-term outlook for the cannabis capital markets. According to Zamparo, quality names in the space that are producing profits are still expected to trade between 10 and 30 percent below averages seen just months ago.

Based on this projection, the analyst sees the cannabis capital markets getting less attention than they did during the second half of last year.

While cannabis names have faced increased scrutiny from investors, there is also now the coronavirus effect to consider. Canadian cannabis investments face a particular threat when it comes to the effects of COVID-19 in the midst of a significant impact to the global capital markets.

In 2019, the marijuana industry suffered a dramatic drop off from the previous rush status attached to the space. During the year, the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ), which holds a basket of the biggest names in the cannabis public markets, suffered a drop of 44.04 percent.

Zamparo went as far as to speculate that the current and projected landscape for investments will lead to the shutdown of cannabis companies, a move that he sees as ultimately “necessary” for the industry.

In the event that investors are feeling worried about putting money into the sector at all, Zamparo stressed attention to “a hyper-focus on balance sheet strength,” which in his view should help in the long run against potential downturns in the space.

What about the US market, which continues to expand and offers a counterbalance in enthusiasm to the Canadian names available? In the CIBC note, Zamparo wrote:

“We continue to view US operations (or at the very least, optionality) as an important asset, but with investors in sell-mode, it is critical to examine what potential floor values are in the cannabis universe.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

A middling Canadian cannabis producer announced an executive turnover plan this week after receiving a critical investor letter in September.

Meanwhile, a Canadian exchange-traded fund (ETF) company released lists of new additions to both of its cannabis funds as part of its quarterly rebalancing.

Keep reading... Show less
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here:

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less